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Abstract
The nose is the anatomical site usually recommended for methi-
cillin-resistant Staphylococcus aureus (MRSA) screening. Other
sites are also recommended, but are more controversial. We
showed that the sensitivities of MRSA detection from nasal
swabs alone were 48% and 62% by culture or by rapid PCR test,
respectively. These percentages increased to 79% and 92% with
the addition of groin swabs, and to 96% and 99% with the addi-
tion of groin and throat swabs. In conclusion, neither by culture
nor by rapid PCR test is nose sampling alone sufﬁcient for
MRSA detection. Additional anatomical sites should include at
least the groin and throat.
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Methicillin resistant Staphylococcus aureus (MRSA) is responsi-
ble for a large number of healthcare-associated and, more
recently, community-acquired infections worldwide [1]. Rapid
and accurate detection of MRSA in the laboratory is a key
element for early therapy and for implementation of control
measures to prevent onward transmission from carriers
[2–6]. Recently developed PCR-based methods have the
potential to conﬁrm or refute MRSA carriage in individual
patients within 2 h. Most of these methods have been evalu-
ated for nose specimens only.
The recommended screening sites vary between national
guidelines. In low-incidence countries, such as The Nether-
lands, sampling includes swabs of the nose, the throat, the
perineum, wounds, catheter insertion sites, sputum, and
urine (http://www.wip.nl). British guidelines recommend
screening of anterior nares, skin lesions and wounds, sites of
catheters, catheters, urine, the groin/perineum, tracheostomy
and other skin breaks, and sputum [7]. In addition, the
‘throat should be considered’. French guidelines propose a
nose specimen and at least a specimen of another site
(wound or skin lesion) (http://sf2h.net). US guidelines recom-
mend cultures of the nares. Perirectal and wound cultures
are optional [8]. These differences in guidelines reﬂect the
controversy about which anatomical sites should be included
for MRSA detection. For instance, Baker et al. [9] reported
that extranasal MRSA colonization was rare, whereas Bignar-
di and Lowes [10] claimed that throat swabs identiﬁed more
cases than nose swabs.
The objective of the present study was to evaluate the
additional value of sampling extranasal sites for the detection
of MRSA, by culture and by a rapid PCR test (Xpert MRSA;
Cepheid, Sunnyvale, CA, USA).
The University Hospital of Lausanne is an 870-bed ter-
tiary-care hospital. Active surveillance cultures or rapid PCR
tests form part of the MRSA control programme. This
includes initial screening of the following patients: (i) patients
transferred from a foreign hospital or a nursing home; (ii)
room-mates of newly identiﬁed MRSA-infected/colonized
patients; and (iii) patients hospitalized in a ward with active
nosocomial transmission. It also includes follow-up screening
from: (iv) re-hospitalized patients known to have been posi-
tive for MRSA during a previous hospitalization; and (v) con-
trols after MRSA decolonization. Before June 2009, all
analyses were performed by culture. Thereafter, a rapid PCR
test was implemented for indications (i), (ii) and (iv)
described above, and for admission and discharge from adult
intensive-care units. Screening specimens included swabs
from the nose, the throat, the groin, wounds, if present,
urine, if a catheter was present, and other clinically infected
sites. An MRSA screening was deﬁned as positive if at least
one specimen (= one site) was positive out of the total num-
ber of specimens taken.
From 2006 to 2009, 12 456 MRSA screenings were per-
formed by culture, with separate analyses for the nose,
throat, and groin. If present, other specimens included swabs
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of wounds, urine, if a catheter was present, sputum, or
others. We retrospectively evaluated the contribution of dif-
ferent anatomical sites for the detection of MRSA by culture
during this period. Swab (sterile transport swab; Copan,
Brescia, Italy) specimens were individually inoculated onto an
enrichment broth (m-Staphylococcus broth; Difco, Becton
Dickinson, Basel, Switzerland), which was incubated over-
night before being used to inoculate an MRSA-Select plate
(Bio-Rad, Marnes-la-Coquette, France). This plate was incu-
bated overnight, and characteristic colonies were further
identiﬁed by conventional tests. In total, 3137 (25%) screen-
ings had at least one positive specimen (presence of MRSA).
MRSA was recovered from 1509 of 12 456 (12%) nose
swabs, 1923 of 12 456 (15%) throat swabs, 1984 of 12 456
(16%) groin swabs, 638 of 3384 wound samples (19%), 203
of 3314 (6%) urine samples, 29 of 144 (20%) sputum speci-
mens, and 38 of 218 (17%) other specimens. The sensitivity
of each single site for MRSA detection and the sensitivities
of different combinations of sites are presented in Table 1.
In our study, the sensitivity of nasal culture (48%) was lower
than in previous studies. Coello et al. [11], Girou et al. [12],
Lucet et al. [13], Meurman et al. [14] and Marshal and Spel-
man [15] reported 78%, 84%, 78%, 67% and 69% sensitivity
for nose swab culture, respectively. Throat swabs were not
cultured in the ﬁrst three studies, which could explain the
differences from the last two studies. In fact, if the throat
specimen is added to the nose and groin specimens, extra
cases of exclusive throat carriage will be identiﬁed, resulting
in a lower sensitivity of other specimens. The lower sensitiv-
ity of nose specimens observed in our study can also be par-
tially explained by the fact that screenings for control after
decolonization were included in our dataset. Our decoloniza-
tion procedure included mupirocin nasal ointment, chlorhexi-
dine body wash and chlorhexidine mouth rinse for 5 days.
Nasal mupirocin could have an extended effect on the nose.
This hypothesis is corroborated by the subset analysis of
screenings performed as controls after topical decoloniza-
tion. On comparison of the proportions by the chi-square
test, the sensitivity of detection of nose screening was statis-
tically lower in this subgroup (334/993, 35%) than the sensi-
tivity of remaining screenings (1175/2144, 55%, p <0.001).
Finally, another hypothesis might be that the colonization of
different anatomical sites depends on the bacterial genotype.
In order to evaluate this hypothesis, we stratiﬁed our data
according to the four predominant clones that were
observed during the study period (A, sequence type (ST)45–
staphylococcal cassette chromosome (SCC)mecIV; B, ST105–
SCCmecII; C, ST8–SCCmecIV; D, ST228–SCCmecI) [16].
Statistical analyses were performed by use of the chi-square
test. Screening of the nose alone detected 24 of 43 (56%),
635 of 1315 (48%), 69 of 126 (55%) and 624 of 1322 (47%)
of MRSA cases in clones A, B, C and D, respectively (no
signiﬁcant difference among clones). Screening of the groin
alone detected 30 of 43 (70%), 735 of 1315 (56%), 54 of 126
(43%) and 1001 of 1322 (76%) of MRSA cases in clones A, B,
C and D, respectively (clone A vs. clone C, p 0.002; clone D
vs. clones B and C, p £0.001). Screening of the throat alone
detected 26 of 43 (60%), 828 of 1315 (63%), 89 of 126
(71%) and 781 of 1322 (59%) of MRSA cases in clones A, B,
C and D, respectively (no signiﬁcant difference among
clones). Thus, in our setting, a statistically signiﬁcantly higher
proportion of MRSA cases was detected with groin speci-
mens in clones A and D.
From June 2009 to December 2009, 2876 screenings for
MRSA were performed by GeneXpert. Double swabs of the
Cepheid collection device (Copan) were used for the rapid
PCR test (Xpert MRSA; Cepheid), according to the manufac-
turer’s recommendations. The contributions of different
TABLE 1. Sensitivity of different screening sites and combinations for detection of methicillin-resistant Staphylococcus aureus
(MRSA) by culture and by PCR rapid test (Xpert MRSA)
Culturea PCR rapid testb
Screening sites No. of positive samples Sensitivity, % (95% CI) No. of positive samples Sensitivity, % (95% CI)
Single sites
Nose 1509 48 (46–50) 193 62 (56–67)
Groin 1984 63 (62–65) 213 68 (63–73)
Throat 1923 61 (60–63) 134 43 (37–49)
Combinations of sites
Nose and groin 2475 79 (77–80) 288 92 (89–95)
Nose and throat 2377 76 (74–77) 230 74 (68–78)
Groin and throat 2799 89 (88–90) 258 83 (78–87)
Nose, groin, and throat 3002 96 (95–96) 309 99 (97–100)
Nose, groin, throat, and wounds 3113 99 (99–99) 310 99 (97–100)
Nose, groin, throat, wounds, and others 3137 100 312 100
aPeriod, 2006–2009; positive screenings (‡1 positive site), 3137.
bPeriod, 2009; positive screenings (‡1 positive site), 312.
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anatomical sites for MRSA detection by the rapid PCR test
were evaluated during this period. For each case, nose,
throat and groin swabs were analysed separately. Other
specimens, such as swabs of wounds, urine, if a catheter was
present, or sputum were also included, if present. In total,
312 (11%) screenings had at least one positive specimen
(presence of MRSA). MRSA was recovered from 193 of
2876 (7%) nose swabs, 134 of 2876 (5%) throat swabs, 213
of 2876 (7%) groin swabs, 23 of 170 wound specimens
(14%), 18 of 1437 (1%) urine specimens, none of one (0%)
sputum specimen, and one of 11 (9%) other specimens. The
sensitivities for MRSA detection of single sites or combina-
tions of sites are presented in Table 1. These results showed
that the sensitivity of nasal swabs alone was 62%.
In our setting, addition of throat swabs to nose and groin
swabs increased the MRSA detection rate from 79% to 96%
by culture and from 92% to 99% by the rapid PCR test,
respectively. Wassengerg et al. [17] recently reported that
the addition of throat swabs to nasal swabs increased the
detection rate from 69% to 70% with BD GeneOhm (BD
Diagnostics, San Diego, CA, USA), and from 56% to 66%
with Xpert. In comparison with culture, the performance of
Xpert MRSA was lower in throat swabs than in specimens
from other screening sites [18].
In conclusion, neither by culture nor by rapid PCR test is
nose sampling alone sufﬁcient for MRSA detection. Addi-
tional anatomical sites should include at least swabs from the
groin and throat. In an attempt to limit MRSA screening
costs, it is probably worth pooling nasal and/or groin and/or
throat swabs, as proposed by others [19], rather than using
only one or two of these important screening sites.
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